89bio to participate in the h.c. wainwright 24th annual global investment conference

San francisco, sept. 07, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that company's management will participate in a fireside chat and one-on-one investor meetings at the h.c. wainwright 24th annual global investment conference on monday, september 12, 2022 at 4:00 pm et.
ETNB Ratings Summary
ETNB Quant Ranking